TORONTO, January 25, 2018 (Newswire.com) - In a live session upcoming on Tuesday, February 13, 2018 at 11 a.m. EST, experts from Biotelemetry and AMRA will discuss alternative methods to BMI for determining body composition in clinical trials.
Webinar Details: Body Composition in Clinical Trials – From BMI to MRI
According to the WHO, obesity has reached epidemic proportions globally, with at least 2.8 million people dying each year as a result of being overweight or obese. The number of obese children and adolescents (aged five to 19 years) worldwide has risen tenfold in the past four decades. Obesity is a major risk factor for heart disease, stroke, osteoarthritis, diabetes, liver disease such as non-alcoholic steatohepatitis (NASH), and certain cancers. Muscular dystrophies, such as Duchenne, myotonic, facioscapulohumeral, etc., currently have no cure. Staging and progression of these conditions can be measured by the amount of muscle tissue that has been replaced by fat. As pharmaceutical companies attempt to develop treatments for these noncommunicable, obesity-related diseases and for the different muscular dystrophies, it is important to monitor body composition as both an efficacy and safety endpoint. The traditional body composition measurement has been BMI. Although BMI is a rough estimate of how over- or underweight a person is, it does not provide information about how much of the weight comes from muscle, how much comes from fat and how these tissues are affected by the treatment.
Join BioTelemetry Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, as they present alternative, noninvasive imaging methods to determine body composition. These imaging methods range from the most simplistic thickness measurements from ultrasound to the more advanced measurements of fat distribution, muscle tissue, and diffuse infiltration of fat in muscle and liver tissue from DXA, CT and MRI.
The speakers will discuss:
- Advantages and disadvantages of noninvasive imaging methods
- Where each modality is appropriate
- How to successfully implement the modalities in clinical trials
- The latest advances in body composition measurements obtained from rapid, highly standardized, whole-body MRI
Register today to learn about the alternative, noninvasive imaging methods available to determine body composition in your clinical trial.
For more information about this complimentary webinar, visit: Body Composition in Clinical Trials – From BMI to MRI
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx
Tel: +1 (416) 977-6555 ext 352